Compare DEA & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DEA | PCRX |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2014 | 2010 |
| Metric | DEA | PCRX |
|---|---|---|
| Price | $22.99 | $23.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $23.49 | ★ $30.25 |
| AVG Volume (30 Days) | 335.1K | ★ 572.7K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.92% | N/A |
| EPS Growth | 50.00 | ★ 107.44 |
| EPS | ★ 0.27 | 0.16 |
| Revenue | $336,099,000.00 | ★ $541,533,000.00 |
| Revenue This Year | $5.20 | $6.78 |
| Revenue Next Year | $3.63 | $8.54 |
| P/E Ratio | ★ $84.26 | $148.81 |
| Revenue Growth | 11.27 | ★ 26.04 |
| 52 Week Low | $7.88 | $18.80 |
| 52 Week High | $24.94 | $27.99 |
| Indicator | DEA | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 60.74 | 57.81 |
| Support Level | $21.64 | $22.57 |
| Resistance Level | $23.70 | $23.94 |
| Average True Range (ATR) | 0.45 | 0.75 |
| MACD | 0.18 | 0.07 |
| Stochastic Oscillator | 89.55 | 73.42 |
Easterly Government Properties Inc is a real estate investment trust. The company is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. It generates all its revenue by leasing its properties to such agencies. The company operates in single segment for the purposes of assessing performance and making operating decisions.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.